|
業務類別
|
Biotechnology |
|
業務概覽
|
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, aBCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America. |
| 公司地址
| Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800 |
| 電話號碼
| +32 15342900 |
| 傳真號碼
| +32 15342901 |
| 公司網頁
| https://www.glpg.com |
| 員工數量
| 704 |
| Mr. Thad Allen Huston |
Chief Financial Officer, Chief Operating Officer and Executive Vice President |
-- |
27/03/2025 |
| Dr. Paulus Stoffels |
Chairman of the Board and Chief Executive Officer |
美元 772.50K |
27/03/2025 |
| Ms. Valeria Cnossen |
General Counsel and Executive Vice President |
-- |
27/03/2025 |
| Ms. Annelies Missotten |
Chief Human Resources Officer and Executive Vice President |
-- |
27/03/2025 |
|
|
| Dr. Susanne Schaffert, PhD |
Independent Director |
27/03/2025 |
| Mr. Jerome Contamine |
Lead Independent Director |
27/03/2025 |
| Dr. Paulus Stoffels |
Chairman of the Board and Chief Executive Officer |
27/03/2025 |
| Mr. Peter Guenter |
Independent Director |
27/03/2025 |
| Mr. Andrew D. Dickinson |
Director |
27/03/2025 |
| Mr. Simon John Sturge |
Independent Director |
27/03/2025 |
| Dr. Linda Higgins, PhD |
Director |
27/03/2025 |
| Dr. Elisabeth Svanberg |
Independent Director |
27/03/2025 |
| Mr. Oleg Nodelman |
Director |
27/03/2025 |
|
|
|
|
